Go to
JCI Insight
Citations to this article
Alena Gros, … , James C. Yang, Steven A. Rosenberg
Published October 14, 2019
Citation Information: J Clin Invest. 2019;129(11):4992-5004. https://doi.org/10.1172/JCI127967.
Citation Information: J Clin Invest. 2019;129(11):4992-5004. https://doi.org/10.1172/JCI127967.
Abstract
Tumor-resident lymphocytes can mount a response against neoantigens expressed in microsatellite-stable gastrointestinal (GI) cancers, and adoptive transfer of neoantigen-specific lymphocytes has demonstrated antitumor activity in selected patients. However, whether peripheral blood could be used as an alternative minimally invasive source to identify lymphocytes targeting neoantigens in patients with GI cancer with relatively low mutation burden is unclear. We used a personalized high-throughput screening strategy to investigate whether PD-1 expression in peripheral blood could be used to identify CD8+ or CD4+ lymphocytes recognizing neoantigens identified by whole-exome sequencing in 7 patients with GI cancer. We found that neoantigen-specific lymphocytes were preferentially enriched in the CD8+PD-1+/hi or CD4+PD-1+/hi subsets, but not in the corresponding bulk or PD-1– fractions. In 6 of 7 individuals analyzed we identified circulating CD8+ and CD4+ lymphocytes targeting 6 and 4 neoantigens, respectively. Moreover, neoantigen-reactive T cells and a T cell receptor (TCR) isolated from the CD8+PD-1+ subsets recognized autologous tumor, albeit at reduced levels, in 2 patients with available cell lines. These data demonstrate the existence of circulating T cells targeting neoantigens in GI cancer patients and provide an approach to generate enriched populations of personalized neoantigen-specific lymphocytes and isolate TCRs that could be exploited therapeutically to treat cancer.
Authors
Alena Gros, Eric Tran, Maria R. Parkhurst, Sadia Ilyas, Anna Pasetto, Eric M. Groh, Paul F. Robbins, Rami Yossef, Andrea Garcia-Garijo, Carlos A. Fajardo, Todd D. Prickett, Li Jia, Jared J. Gartner, Satyajit Ray, Lien Ngo, John R. Wunderllich, James C. Yang, Steven A. Rosenberg
Total citations by year
Citation information
Citations to this article (99)
| Title and authors | Publication | Year |
|---|---|---|
|
Utilization of primary tumor samples for cancer neoantigen discovery
Leko V, Groh E, Levi ST, Copeland AR, White BS, Gasmi B, Li Y, Hill V, Gurusamy D, Levin N, Kim SP, Sindiri S, Gartner JJ, Prickett TD, Parkhust M, Lowery FJ, Goff SL, Rosenberg SA, Robbins P |
Journal for Immunotherapy of Cancer | 2025 |
|
Genetics and biology of pancreatic ductal adenocarcinoma
Ying H, Kimmelman AC, Bardeesy N, Kalluri R, Maitra A, DePinho RA |
Genes & Development | 2025 |
|
Isolation of a tumor neoantigen specific CD8+ TCR from a skin biopsy of a vaccination site
Roberti MP, Charoentong P, Lyu Y, Meyer M, Eichmüller SB, Schmidt P, Momburg F, Cetin M, Hartmann F, Valous NA, Stenzinger A, Michel L, Lichter P, Schneeweiss A, Thewes V, Fremd C, Zörnig I, Jäger D |
Oncoimmunology | 2025 |
|
The Efficacy of Curcumin in Reducing Immunosuppressive States of Peripheral Blood Mononuclear Cells Extracted From Oral Squamous Cell Carcinoma Patients: An In Vitro Study
Dash P, Nayak S, Parida PK |
Cureus | 2025 |
|
Radical hemithorax radiotherapy induces an increase in circulating PD-1+ T lymphocytes and in the soluble levels of PD-L1 in malignant pleural mesothelioma patients: a possible synergy with PD-1/PD-L1 targeting treatment?
Revelant A, Gessoni F, Montico M, Dhibi R, Brisotto G, Casarotto M, Zanchetta M, Paduano V, Sperti F, Evangelista C, Giordari F, De Re V, Trovò M, Minatel E, Mascarin M, Steffan A, Muraro E |
Frontiers in Immunology | 2025 |
|
Influence of polyfunctional Tbet+ T cells on specific clinical events in chronic lymphocytic leukaemia
Lim YJ, Duckworth AD, Clarke K, Kennedy P, Karpha I, Oates M, Gornall M, Kalakonda N, Slupsky JR, Pettitt AR |
Frontiers in Immunology | 2025 |
|
The Optimal Timing of Anti-PD-1 Antibody Combined with Chemotherapy Administration in NSCLC Patients
Yachang Huo, Dan Wang, Shuangning Yang, Yujie Xu, Guohui Qin, Chenhui Zhao, Qingyang Lei, Qitai Zhao, Yaqing Liu, Kaiyuan Guo, Songyun Ouyang, Ting Sun, Hongmin Wang, Feifei Fan, Na Han, Hong Liu, Hongjie Chen, Lijun Miao, Li Liu, Yuqing Duan, Wei Lv, Lihua Liu, Zhixin Zhang, Shundong Cang, Liping Wang, Yi Zhang |
Journal for immunotherapy of cancer | 2024 |
|
mRNA-based precision targeting of neoantigens and tumor-associated antigens in malignant brain tumors
Trivedi V, Yang C, Klippel K, Yegorov O, von Roemeling C, Hoang-Minh L, Fenton G, Ogando-Rivas E, Castillo P, Moore G, Long-James K, Dyson K, Doonan B, Flores C, Mitchell DA |
Genome Medicine | 2024 |
|
ES-SCLC Patients with PD-L1(+) CTCs and High Percentages of CD8(+)PD-1(+)T Cells in Circulation Benefit from Front-Line Immunotherapy Treatment.
Xagara A, Roumeliotou A, Kokkalis A, Tsapakidis K, Papakonstantinou D, Papadopoulos V, Samaras I, Chantzara E, Kallergi G, Kotsakis A |
Biomedicines | 2024 |
|
Circulating T cells: a promising biomarker of anti-PD-(L)1 therapy.
Hou J, Yang X, Xie S, Zhu B, Zha H |
Frontiers in immunology | 2024 |
|
Adjuvant PD-1 Checkpoint Inhibition in Early Cutaneous Melanoma: Immunological Mode of Action and the Role of Ultraviolet Radiation
Brandlmaier M, Hoellwerth M, Koelblinger P, Lang R, Harrer A |
Cancers | 2024 |
|
Neutrophil diversity is associated with T-cell immunity and clinical relevance in patients with thyroid cancer.
Lee SE, Koo BS, Sun P, Yi S, Choi NR, Yoon J, Kim SY, Kim SK, Park S, Lakhani A, O'Keeffe S, Park JO, Kang DH, Kang YE |
Cell Death Discovery | 2024 |
|
Deciphering the tumor immune microenvironment from a multidimensional omics perspective: insight into next-generation CAR-T cell immunotherapy and beyond
Zhou Z, Wang J, Wang J, Yang S, Wang R, Zhang G, Li Z, Shi R, Wang Z, Lu Q |
Molecular Cancer | 2024 |
|
Manipulating regulatory T cells: is it the key to unlocking effective immunotherapy for pancreatic ductal adenocarcinoma?
Smith H, Arbe-Barnes E, Shah EA, Sivakumar S |
Frontiers in immunology | 2024 |
|
KSHV infection of B cells primes protective T cell responses in humanized mice
Caduff N, Rieble L, Böni M, McHugh D, Roshan R, Miley W, Labo N, Barman S, Trivett M, Bosma DM, Rühl J, Goebels N, Whitby D, Münz C |
Nature Communications | 2024 |
|
Immunomic longitudinal profiling of the NeoPembrOv trial identifies drivers of immunoresistance in high-grade ovarian carcinoma
Le Saux O, Ardin M, Berthet J, Barrin S, Bourhis M, Cinier J, Lounici Y, Treilleux I, Just PA, Bataillon G, Savoye AM, Mouret-Reynier MA, Coquan E, Derbel O, Jeay L, Bouizaguen S, Labidi-Galy I, Tabone-Eglinger S, Ferrari A, Thomas E, Ménétrier-Caux C, Tartour E, Galy-Fauroux I, Stern MH, Terme M, Caux C, Dubois B, Ray-Coquard I |
Nature Communications | 2024 |
|
Human effector CD8+ T cells with an activated and exhausted-like phenotype control tumour growth in vivo in a humanized tumour model
Mietz J, Kaulfuss M, Egli L, Opitz L, Münz C, Chijioke O |
EBioMedicine | 2024 |
|
Exhaustion of T cells after renal transplantation
Wang X, Zhang J, Zhong P, Wei X |
Frontiers in Immunology | 2024 |
|
Peripheral immune biomarkers for immune checkpoint inhibition of solid tumours.
Goswami M, Toney NJ, Pitts SC, Celades C, Schlom J, Donahue RN |
Clinical and translational medicine | 2024 |
|
[Antitumor Study of Neoantigen-reactive T Cells Co-expressing IL-7 and CCL19
in Mouse Lung Cancer].
Wu D, Li C, Wang Y, He Z, Jin C, Guo M, Chen R, Zhou C |
Zhongguo fei ai za zhi = Chinese journal of lung cancer | 2024 |
|
Transient-resting culture after activation enhances the generation of CD8(+) stem cell-like memory T cells from peripheral blood mononuclear cells.
Chen G, Yuan L, Zhang Y, Li T, You H, Han L, Qin P, Wang Y, Liu X, Guo J, Zhang M, Zhang K, Li L, Yuan P, Xu B, Gao Q |
Translational oncology | 2024 |
|
Delivery of IL-12 by neoantigen-reactive T cells promotes antitumor immunity in murine osteosarcoma mode
Tian C, Sun X, Zhu H, Zhou M, Chen Q, Min D, Huang Y, Han K |
Immunotherapy Advances | 2024 |
|
Preclinical data and design of a phase I clinical trial of neoantigen-reactive TILs for advanced epithelial or ICB-resistant solid cancers
Palomero J, Galvao V, Creus I, Lostes J, Aylagas M, Marín-Bayo A, Rotxés M, Sanz M, Lozano-Rabella M, Garcia-Garijo A, Yuste-Estevanez A, Grases D, Díaz-Gómez J, González J, Navarro JF, Gartner JJ, Braña I, Villalobos X, Bayó-Puxan N, Jiménez J, Palazón AN, Muñoz S, Villacampa G, Piris-Giménez A, Barba P, Codinach M, Rodríguez L, Querol S, Muñoz-Couselo E, Tabernero J, Martín-Lluesma S, Gros A, Garralda E |
Immuno-Oncology and Technology | 2024 |
|
Tumor cells fail to present MHC-II restricted epitopes derived from oncogenes to CD4+ T cells
Spencer Brightman, Martin Naradikian, Rukman Thota, Angelica Becker, Leslie Montero, Milad Bahmanof, Ashmitaa Premlal, Jason Greenbaum, Bjoern Peters, Ezra Cohen, Aaron Miller, Stephen Schoenberger |
JCI Insight | 2023 |
|
Immunotherapies in rare cancers
Vivekanandhan S, Bahr D, Kothari A, Ashary MA, Baksh M, Gabriel E |
Molecular Cancer | 2023 |
|
TCR-engineered T cell therapy in solid tumors: State of the art and perspectives
Baulu E, Gardet C, Chuvin N, Depil S |
Science Advances | 2023 |
|
Stratification of PD-1 blockade response in melanoma using pre- and post-treatment immunophenotyping of peripheral blood
Edner NM, Ntavli E, Petersone L, Wang CJ, Fabri A, Kogimtzis A, Ovcinnikovs V, Ross EM, Heuts F, Elfaki Y, Houghton LP, Talbot T, Sheri A, Pender A, Chao D, Walker LS |
2023 | |
|
CD103 and CD39 coexpression identifies neoantigen-specific cytotoxic T cells in colorectal cancers with low mutation burden
van den Bulk J, van der Ploeg M, Ijsselsteijn ME, Ruano D, van der Breggen R, Duhen R, Peeters KC, Fariña-Sarasqueta A, Verdegaal EM, van der Burg SH, Duhen T, de Miranda NF |
Journal for ImmunoTherapy of Cancer | 2023 |
|
Systemic immune modulation by stereotactic radiotherapy in early-stage lung cancer.
Gkika E, Firat E, Adebahr S, Graf E, Popp I, Radicioni G, Lo SS, Nestle U, Nicolay NH, Niedermann G, Duda DG, Grosu AL |
npj Precision Oncology | 2023 |
|
Neoantigen-targeted CD8(+) T cell responses with PD-1 blockade therapy.
Puig-Saus C, Sennino B, Peng S, Wang CL, Pan Z, Yuen B, Purandare B, An D, Quach BB, Nguyen D, Xia H, Jilani S, Shao K, McHugh C, Greer J, Peabody P, Nayak S, Hoover J, Said S, Jacoby K, Dalmas O, Foy SP, Conroy A, Yi MC, Shieh C, Lu W, Heeringa K, Ma Y, Chizari S, Pilling MJ, Ting M, Tunuguntla R, Sandoval S, Moot R, Hunter T, Zhao S, Saco JD, Perez-Garcilazo I, Medina E, Vega-Crespo A, Baselga-Carretero I, Abril-Rodriguez G, Cherry G, Wong DJ, Hundal J, Chmielowski B, Speiser DE, Bethune MT, Bao XR, Gros A, Griffith OL, Griffith M, Heath JR, Franzusoff A, Mandl SJ, Ribas A |
Nature | 2023 |
|
Deciphering the tumour immune microenvironment cell by cell
Nabhan M, Egan D, Kreileder M, Zhernovkov V, Timosenko E, Slidel T, Dovedi S, Glennon K, Brennan D, Kolch W |
2023 | |
|
Rapid TCR:Epitope Ranker (RAPTER): a primary human T cell reactivity screening assay pairing epitope and TCR at single cell resolution
Deering RP, Blumenberg L, Li L, Dhanik A, Jeong S, Pourpe S, Song H, Boucher L, Ragunathan S, Li Y, Zhong M, Kuhnert J, Adler C, Hawkins P, Gupta NT, Moore M, Ni M, Hansen J, Wei Y, Thurston G |
Scientific Reports | 2023 |
|
Cell surface marker-based capture of neoantigen-reactive CD8(+) T-cell receptors from metastatic tumor digests.
Chatani PD, Lowery FJ, Parikh NB, Hitscherich KJ, Yossef R, Hill V, Gartner JJ, Paria B, Florentin M, Ray S, Bera A, Parkhust M, Robbins P, Krishna S, Rosenberg SA |
Journal for ImmunoTherapy of Cancer | 2023 |
|
Glycolytic neutrophils accrued in the spleen compromise anti-tumour T cell immunity in breast cancer.
Wang Y, Xu M, Sun J, Li X, Shi H, Wang X, Liu B, Zhang T, Jiang X, Lin L, Li Q, Huang Y, Liang Y, Hu M, Zheng F, Zhang F, Sun J, Shi Y, Wang Y |
Nature metabolism | 2023 |
|
The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells
Li J, Xiao Z, Wang D, Jia L, Nie S, Zeng X, Hu W |
Molecular Cancer | 2023 |
|
Tumor-Infiltrating Lymphocytes and Adoptive Cell Therapy: State of the Art in Colorectal, Breast and Lung Cancer
ZEMANEK T, NOVA Z, NICODEMOU A |
2023 | |
|
Harnessing T cell exhaustion and trogocytosis to isolate patient-derived tumor-specific TCR
Manfredi F, Stasi L, Buonanno S, Marzuttini F, Noviello M, Mastaglio S, Abbati D, Potenza A, Balestrieri C, Cianciotti BC, Tassi E, Feola S, Toffalori C, Punta M, Magnani Z, Camisa B, Tiziano E, Lupo-Stanghellini MT, Branca RM, Lehtiö J, Sikanen TM, Haapala MJ, Cerullo V, Casucci M, Vago L, Ciceri F, Bonini C, Ruggiero E |
Science Advances | 2023 |
|
A prospective study of immune responses in patients with lung metastases treated with stereotactic body radiotherapy with or without concurrent systemic treatment.
Duda D, Gkika E, Firat E, Adebahr S, Graf E, Eichhorst A, Radicioni G, Lo S, Spohn S, Nestle U, Nicolay N, Niedermann G, Grosu AL |
Research square | 2023 |
|
Phenotypic Signatures of Circulating Neoantigen-Reactive CD8+ T Cells in Patients with Metastatic Cancers
Yossef R, Krishna S, Sindiri S, Lowery FJ, Copeland AR, Gartner JJ, Parkhurst MR, Parikh NB, Hitscherich KJ, Levi ST, Chatani PD, Zacharakis N, Levin N, Vale NR, Nah SK, Dinerman A, Hill VK, Ray S, Bera A, Levy L, Jia L, Kelly MC, Goff SL, Robbins PF, Rosenberg SA |
Cancer Cell | 2023 |
|
Generation of Tumor-Specific Cytotoxic T Cells From Blood via In Vitro Expansion Using Autologous Dendritic Cells Pulsed With Neoantigen-Coupled Microbeads
A Kiessling, K Ramanathan, O Nilsson, L Notari, S Renken, R Kiessling, H Grönlund, S Wickström |
Frontiers in Oncology | 2022 |
|
The role of biomarkers in personalized immunotherapy
K Sankar, J Ye, Z Li, L Zheng, W Song, S Hu-Lieskovan |
Biomarker Research | 2022 |
|
The role of CD4 T cells in rejection of solid tumors
L Poncette, J Bluhm, T Blankenstein |
Current Opinion in Immunology | 2022 |
|
Isolation of TCR genes with tumor-killing activity from tumor-infiltrating and circulating lymphocytes in a tumor rejection cynomolgus macaque model
K Terada, K Kondo, H Ishigaki, A Nagashima, H Satooka, S Nagano, K Masuda, T Kawamura, T Hirata, K Ogasawara, Y Itoh, H Kawamoto, Y Agata |
Molecular Therapy — Oncolytics | 2022 |
|
Identification of shared tumor epitopes from endogenous retroviruses inducing high-avidity cytotoxic T cells for cancer immunotherapy
P Bonaventura, V Alcazer, V Mutez, L Tonon, J Martin, N Chuvin, E Michel, R Boulos, Y Estornes, J Valladeau-Guilemond, A Viari, Q Wang, C Caux, S Depil |
Science Advances | 2022 |
|
Characteristics and Clinical Significance of T-Cell Receptor Repertoire in Hepatocellular Carcinoma
Z Wang, Y Zhong, Z Zhang, K Zhou, Z Huang, H Yu, L Liu, S Liu, H Yang, J Zhou, J Fan, L Wu, Y Sun |
Frontiers in immunology | 2022 |
|
Splenic and PB immune recovery in neoadjuvant treated gastrointestinal cancer patients
K Cole, Q Ly, M Hollingsworth, J Cox, K Fisher, J Padussis, J Foster, L Vargas, J Talmadge |
International Immunopharmacology | 2022 |
|
Pseudocowpox virus, a novel vector to enhance the therapeutic efficacy of antitumor vaccination
R Ramos, C Tosch, F Kotsias, M Claudepierre, D Schmitt, C RemyZiller, C Hoffmann, M Ricordel, V Nourtier, I Farine, L Laruelle, J Hortelano, C SpringGiusti, C Sedlik, C Tourneau, C Hoffmann, N Silvestre, P Erbs, K Bendjama, C Thioudellet, E Quemeneur, E Piaggio, K Rittner |
IBMS BoneKEy | 2022 |
|
BRCA-Mutated Pancreatic Cancer: From Discovery to Novel Treatment Paradigms
Devico Marciano N, Kroening G, Dayyani F, Zell JA, Lee FC, Cho M, Valerin JG |
Cancers | 2022 |
|
T-Cell Receptor Repertoire Sequencing and Its Applications: Focus on Infectious Diseases and Cancer
Mazzotti L, Gaimari A, Bravaccini S, Maltoni R, Cerchione C, Juan M, Navarro EA, Pasetto A, Nascimento Silva D, Ancarani V, Sambri V, Calabrò L, Martinelli G, Mazza M |
International journal of molecular sciences | 2022 |
|
TCR repertoire and transcriptional signatures of circulating tumour‐associated T cells facilitate effective non‐invasive cancer detection
Ji F, Chen L, Chen Z, Luo B, Wang Y, Lan X |
Clinical and Translational Medicine | 2022 |
|
Seq2Neo: A Comprehensive Pipeline for Cancer Neoantigen Immunogenicity Prediction
Diao K, Chen J, Wu T, Wang X, Wang G, Sun X, Zhao X, Wu C, Wang J, Yao H, Gerarduzzi C, Liu XS |
International journal of molecular sciences | 2022 |
|
Clinical implications of T cell exhaustion for cancer immunotherapy.
Chow A, Perica K, Klebanoff CA, Wolchok JD |
Nature reviews. Clinical oncology | 2022 |
|
High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer.
Mollavelioglu B, Cetin Aktas E, Cabioglu N, Abbasov A, Onder S, Emiroglu S, Tükenmez M, Muslumanoglu M, Igci A, Deniz G, Ozmen V |
World journal of surgical oncology | 2022 |
|
Potential biomarkers: Identifying powerful tumor specific T cells in adoptive cellular therapy
Ge W, Dong Y, Deng Y, Chen L, Chen J, Liu M, Wu J, Wang W, Ma X |
Frontiers in immunology | 2022 |
|
Immune Phenotypes and Target Antigens of Clonally Expanded Bone Marrow T Cells in Treatment-Naïve Multiple Myeloma
Welters C, Lammoglia Cobo MF, Stein CA, Hsu MT, Ben Hamza A, Penter L, Chen X, Buccitelli C, Popp O, Mertins P, Dietze K, Bullinger L, Moosmann A, Blanc E, Beule D, Gerbitz A, Strobel J, Hackstein H, Rahn HP, Dornmair K, Blankenstein T, Hansmann L |
Cancer immunology research | 2022 |
|
Cellular Cancer Immunotherapy Development and Manufacturing in the Clinic
Fenton GA, Mitchell DA |
Clinical cancer research | 2022 |
|
Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma
Hall MS, Mullinax JE, Cox CA, Hall AM, Beatty MS, Blauvelt J, Innamarato P, Nagle L, Branthoover H, Wiener D, Schachner B, Martinez AJ, Richards AD, Rich CJ, Colón MC, Schell MJ, Teer JK, Khushalani NI, Weber JS, Mulé JJ, Sondak VK, Pilon-Thomas S, Sarnaik AA |
Clinical cancer research | 2022 |
|
Induction of EBV latent membrane protein-2A (LMP2A)-specific T cells and construction of individualized TCR-engineered T cells for EBV-associated malignancies
C Zhang, Q Tan, S Li, L Shen, J Zhang, Y Liu, W Yang, Z Lu |
Journal for ImmunoTherapy of Cancer | 2021 |
|
Soluble immune checkpoints and T-cell subsets in blood as biomarkers for resistance to immunotherapy in melanoma patients
D Machiraju, M Wiecken, N Lang, I Hülsmeyer, J Roth, TE Schank, R Eurich, N Halama, A Enk, JC Hassel |
OncoImmunology | 2021 |
|
Single-Cell TCR and Transcriptome Analysis: An Indispensable Tool for Studying T-Cell Biology and Cancer Immunotherapy
A Pasetto, YC Lu |
Frontiers in immunology | 2021 |
|
The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer
WA Freed-, LJ Lambert, ZA Ely, NB Pattada, A Bhutkar, G Eng, KL Mercer, AP Garcia, L Lin, WM Rideout, WL Hwang, JM Schenkel, AM Jaeger, RT Bronson, PM Westcott, TD Hether, P Divakar, JW Reeves, V Deshpande, T Delorey, D Phillips, OH Yilmaz, A Regev, T Jacks |
Cancer Cell | 2021 |
|
A high OXPHOS CD8 T cell subset is predictive of immunotherapy resistance in melanoma patients
C Li, YP Phoon, K Karlinsey, YF Tian, S Thapaliya, A Thongkum, L Qu, AJ Matz, M Cameron, C Cameron, A Menoret, P Funchain, JM Song, CM Diaz-Montero, B Tamilselvan, JB Golden, M Cartwright, A Rodriguez, C Bonin, A Vella, B Zhou, BR Gastman |
Journal of Experimental Medicine | 2021 |
|
CD8+ T cell differentiation and dysfunction in cancer
M Philip, A Schietinger |
Nature Reviews Immunology | 2021 |
|
The Promise of Personalized TCR-Based Cellular Immunotherapy for Cancer Patients
M Arnaud, S Bobisse, J Chiffelle, A Harari |
Frontiers in immunology | 2021 |
|
A machine learning model for ranking candidate HLA class I neoantigens based on known neoepitopes from multiple human tumor types
JJ Gartner, MR Parkhurst, A Gros, E Tran, MS Jafferji, A Copeland, KI Hanada, N Zacharakis, A Lalani, S Krishna, A Sachs, TD Prickett, YF Li, M Florentin, S Kivitz, SC Chatmon, SA Rosenberg, PF Robbins |
2021 | |
|
Identification of neoantigen-reactive T lymphocytes in the peripheral blood of a patient with glioblastoma
V Leko, G Cafri, R Yossef, B Paria, V Hill, D Gurusamy, Z Zheng, JJ Gartner, TD Prickett, SL Goff, P Robbins, YC Lu, SA Rosenberg |
Journal for ImmunoTherapy of Cancer | 2021 |
|
Anti-tumour effect of neo-antigen-reactive T cells induced by RNA mutanome vaccine in mouse lung cancer
J Sun, J Zhang, H Hu, H Qin, X Liao, F Wang, W Zhang, Q Yin, X Su, Y He, W Li, K Wang, Q Li |
Journal of Cancer Research and Clinical Oncology | 2021 |
|
Genetic and biological hallmarks of colorectal cancer
J Li, X Ma, D Chakravarti, S Shalapour, RA DePinho |
Genes & development | 2021 |
|
TCR signal strength defines distinct mechanisms of T cell dysfunction and cancer evasion
M Shakiba, P Zumbo, G Espinosa-Carrasco, L Menocal, F Dündar, S Carson, E Bruno, F Sanchez-Rivera, S Lowe, S Camara, R Koche, V Reuter, N Socci, B Whitlock, F Tamzalit, M Huse, M Hellmann, D Wells, N Defranoux, D Betel, M Philip, A Schietinger |
Journal of Experimental Medicine | 2021 |
|
Promises and challenges of adoptive T-cell therapies for solid tumours
M Morotti, A Albukhari, A Alsaadi, M Artibani, JD Brenton, SM Curbishley, T Dong, ML Dustin, Z Hu, N McGranahan, ML Miller, L Santana-Gonzalez, LW Seymour, T Shi, PV Loo, C Yau, H White, N Wietek, DN Church, DC Wedge, AA Ahmed |
British Journal of Cancer | 2021 |
|
Biomaterials to enhance antigen-specific T cell expansion for cancer immunotherapy
A Isser, NK Livingston, JP Schneck |
Biomaterials | 2021 |
|
LAG-3-Expressing Tumor-Infiltrating T Cells Are Associated with Reduced Disease-Free Survival in Pancreatic Cancer
L Seifert, I Plesca, L Müller, U Sommer, M Heiduk, J von Renesse, D Digomann, J Glück, A Klimova, J Weitz, M Schmitz, AM Seifert |
Cancers | 2021 |
|
Progress in the Application of Immune Checkpoint Inhibitor-Based Immunotherapy for Targeting Different Types of Colorectal Cancer
R He, Y Lao, W Yu, X Zhang, M Jiang, C Zhu |
Frontiers in Oncology | 2021 |
|
The mutational load and a T-cell inflamed tumour phenotype identify ovarian cancer patients rendering tumour-reactive T cells from PD-1+ tumour-infiltrating lymphocytes
D Salas-Benito, E Conde, I Tamayo-Uria, U Mancheño, E Elizalde, D Garcia-Ros, JM Aramendia, JC Muruzabal, J Alcaide, F Guillen-Grima, JA Minguez, J Amores-Tirado, A Gonzalez-Martin, P Sarobe, JJ Lasarte, M Ponz-Sarvise, CE Andrea, S Hervas-Stubbs |
British Journal of Cancer | 2021 |
|
Identification and Targeting of Mutant Peptide Neoantigens in Cancer Immunotherapy
DJ Verdon, MR Jenkins |
Cancers | 2021 |
|
Direct identification of neoantigen-specific TCRs from tumor specimens by high-throughput single-cell sequencing
YC Lu, Z Zheng, FJ Lowery, JJ Gartner, TD Prickett, PF Robbins, SA Rosenberg |
Journal for ImmunoTherapy of Cancer | 2021 |
|
Targeting public neoantigens for cancer immunotherapy
AH Pearlman, MS Hwang, MF Konig, EH Hsiue, J Douglass, SR DiNapoli, BJ Mog, C Bettegowda, DM Pardoll, SB Gabelli, N Papadopoulos, KW Kinzler, B Vogelstein, S Zhou |
2021 | |
|
Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial
BC Creelan, C Wang, JK Teer, EM Toloza, J Yao, S Kim, AM Landin, JE Mullinax, JJ Saller, AN Saltos, DR Noyes, LB Montoya, W Curry, SA Pilon-Thomas, AA Chiappori, T Tanvetyanon, FJ Kaye, ZJ Thompson, SJ Yoder, B Fang, JM Koomen, AA Sarnaik, DT Chen, JR Conejo-Garcia, EB Haura, SJ Antonia |
Nature Medicine | 2021 |
|
Interaction between intestinal microbiota and tumour immunity in the tumour microenvironment
X Yang, Y Guo, C Chen, B Shao, L Zhao, Q Zhou, J Liu, G Wang, W Yuan, Z Sun |
Immunology | 2021 |
|
Peripheral Blood-Based Biomarkers for Immune Checkpoint Inhibitors
HJ An, HJ Chon, C Kim |
International journal of molecular sciences | 2021 |
|
VENUS, a Novel Selection Approach to Improve the Accuracy of Neoantigens’ Prediction
G Leoni, AM DAlise, FG Tucci, E Micarelli, I Garzia, MD Lucia, F Langone, L Nocchi, G Cotugno, R Bartolomeo, G Romano, S Allocca, F Troise, A Nicosia, A Lahm, E Scarselli |
Human vaccines | 2021 |
|
The Potential of Induced Pluripotent Stem Cells to Advance the Treatment of Pancreatic Ductal Adenocarcinoma
RT Krog, NF de Miranda, AL Vahrmeijer, NG Kooreman |
Cancers | 2021 |
|
Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small-cell lung cancer.
Federico L, McGrail DJ, Bentebibel SE, Haymaker C, Ravelli A, Forget MA, Karpinets T, Jiang P, Reuben A, Negrao MV, Li J, Khairullah R, Zhang J, Weissferdt A, Vaporciyan AA, Antonoff MB, Walsh G, Lin SY, Futreal A, Wistuba I, Roth J, Byers LA, Gaudreau PO, Uraoka N, Cruz AF, Dejima H, Lazcano RN, Solis LM, Parra ER, Lee JJ, Swisher S, Cascone T, Heymach JV, Zhang J, Sepesi B, Gibbons DL, Bernatchez C |
2021 | |
|
Adoptive Cell Therapy—Harnessing Antigen-Specific T Cells to Target Solid Tumours
E Chruściel, Z Urban-Wójciuk, Ł Arcimowicz, M Kurkowiak, J Kowalski, M Gliwiński, T Marjański, W Rzyman, W Biernat, R Dziadziuszko, C Montesano, R Bernardini, N Marek-Trzonkowska |
Cancers | 2020 |
|
TCR Redirected T Cells for Cancer Treatment: Achievements, Hurdles, and Goals
F Manfredi, BC Cianciotti, A Potenza, E Tassi, M Noviello, A Biondi, F Ciceri, C Bonini, E Ruggiero |
Frontiers in immunology | 2020 |
|
Neoantigen-Specific Adoptive Cell Therapies for Cancer: Making T-Cell Products More Personal
V Bianchi, A Harari, G Coukos |
Frontiers in immunology | 2020 |
|
Identification and Clinical Application of Immunological Receptors Targeting Mutated Antigens Expressed by Solid Tumors
A Pasetto |
Cancers | 2020 |
|
Rapid Identification and Evaluation of Neoantigen-reactive T-Cell Receptors From Single Cells
BC Paria, N Levin, FJ Lowery, A Pasetto, DC Deniger, MR Parkhurst, R Yossef, SP Kim, M Florentin, LT Ngo, S Ray, S Krishna, PF Robbins, SA Rosenberg |
Journal of immunotherapy (Hagerstown, Md. : 1997) | 2020 |
|
PD-1 Expression by Lymph Node and Intratumoral Regulatory T Cells Is Associated with Lymph Node Metastasis in Pancreatic Cancer
AM Seifert, A Eymer, M Heiduk, R Wehner, A Tunger, J von Renesse, R Decker, DE Aust, T Welsch, C Reissfelder, J Weitz, M Schmitz, L Seifert |
Cancers | 2020 |
|
Needle in a Haystack: The Naïve Repertoire as a Source of T Cell Receptors for Adoptive Therapy with Engineered T Cells
E DIppolito, KI Wagner, DH Busch |
International journal of molecular sciences | 2020 |
|
Adoptive Cell Therapy Targeting Neoantigens: A Frontier for Cancer Research
Z Wang, YJ Cao |
Frontiers in immunology | 2020 |
|
Peripheral blood immune cell-based biomarkers in anti-PD-1/PD-L1 therapy
KH Kim, CG Kim, EC Shin |
Immune Network | 2020 |
|
New emerging targets in cancer immunotherapy: the role of neoantigens
LD Mattos-Arruda, J Blanco-Heredia, C Aguilar-Gurrieri, J Carrillo, J Blanco |
ESMO Open | 2020 |
|
Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule
A Berezhnoy, BJ Sumrow, K Stahl, K Shah, D Liu, J Li, SS Hao, AD Costa, S Kaul, J Bendell, GM Cote, JJ Luke, RE Sanborn, MR Sharma, F Chen, H Li, G Diedrich, E Bonvini, PA Moore |
Reproduction | 2020 |
|
Emerging Blood-Based Biomarkers for Predicting Response to Checkpoint Immunotherapy in Non-Small-Cell Lung Cancer
S Li, C Zhang, G Pang, P Wang |
Frontiers in immunology | 2020 |
|
Identification of Clonal Neoantigens Derived From Driver Mutations in an EGFR-Mutated Lung Cancer Patient Benefitting From Anti-PD-1
D Wu, Y Liu, X Li, Y Liu, Q Yang, Y Liu, J Wu, C Tian, Y Zeng, Z Zhao, Y Xiao, F Gu, K Zhang, Y Hu, L Liu |
Frontiers in immunology | 2020 |
|
Immunotherapy, Inflammation and Colorectal Cancer
CR Lichtenstern, RK Ngu, S Shalapour, M Karin |
Cells | 2020 |
|
Recent insights into the biology of pancreatic cancer
W Yao, A Maitra, H Ying |
EBioMedicine | 2020 |
|
Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4
J van den Bulk, EM Verdegaal, D Ruano, ME Ijsselsteijn, M Visser, R van der Breggen, T Duhen, M van der Ploeg, NL de Vries, J Oosting, KC Peeters, AD Weinberg, A Farina-Sarasqueta, SH van der Burg, NF de Miranda |
Genome Medicine | 2019 |
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)